Genmab AS 주식 가격. GMAB - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

20.31

매수가

20.06

매도가

20.60

거래량

1,829,681

20.13 일간 변동폭 20.43

0.00 52주 범위 0.00

market_cap

13.42B

전일 종가

20.09

개장가

20.22

최근 거래 시간

20.31

마지막 거래 시간

재정 규모

US$ 37,133,782

VWAP

20.2952

평균 볼륨(3m)

발행 주식

660,745,350

배당수익률

주가수익률

31.81

주당순이익(EPS)

6.59

매출

16.47B

순이익

4.35B

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the stan... Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications. 더 보기

섹터

Biological Pds,ex Diagnstics

산업

Biogenetic (human)

웹사이트

www.genmab.com

본부

Copenhagen, Dnk

설립됨

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker GMAB. The last closing price for Genmab AS was US$20.09. Over the last year, Genmab AS shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Genmab AS currently has 660,745,350 shares in issue. The market capitalisation of Genmab AS is US$13.27 billion. Genmab AS has a price to earnings ratio (PE ratio) of 31.81.

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Results from Arm 1 of the EPCORE® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in...

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily...

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma (NHL) patients New...

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

GMAB - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?

The current share price of Genmab AS is US$ 20.31

How many Genmab AS shares are in issue?

Genmab AS has 660,745,350 shares in issue

What is the market cap of Genmab AS?

The market capitalisation of Genmab AS is USD 13.27B

What is the 1 year trading range for Genmab AS share price?

Genmab AS has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Genmab AS?

The price to earnings ratio of Genmab AS is 31.81

What is the cash to sales ratio of Genmab AS?

The cash to sales ratio of Genmab AS is 8.4

What is the reporting currency for Genmab AS?

Genmab AS reports financial results in DKK

What is the latest annual turnover for Genmab AS?

The latest annual turnover of Genmab AS is DKK 16.47B

What is the latest annual profit for Genmab AS?

The latest annual profit of Genmab AS is DKK 4.35B

What is the registered address of Genmab AS?

The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260

What is the Genmab AS website address?

The website address for Genmab AS is www.genmab.com

Which industry sector does Genmab AS operate in?

Genmab AS operates in the BIOGENETIC (HUMAN) sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
MYSZMy Size Inc	US$ 4.2001 (211.12%)	120.01M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	76.64M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	33.95M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.61k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	120.4M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.91M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.32M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	305.1M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	292.16M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	287.21M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	277.63M